Skip to main content
Livermore
Livermore
ZHEN

UBS Group AG

SEC CIK
0001610520
Latest filing
Aug 13, 2026

APLS holding history

Apellis Pharmaceuticals, Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

APLS overviewAll 13F holders of APLSFull Q2 2026 holdings

Shares (Q2 2026)
0
Sold out in Q2 2026
Value
$0
% of portfolio
0.0%
Quarters held
21
Since Q1 2021
Holdings of APLS by UBS Group AG, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20260$00.0%−6,206,681−100.0%Sold outHolders
Q1 20266,206,681$249.7M<0.1%+2,020,459+48.3%AddedHolders
Q4 20254,186,222$105.2M<0.1%+756,317+22.1%AddedHolders
Q3 20253,429,905$77.6M<0.1%−1,305,406−27.6%ReducedHolders
Q2 20254,735,311$82.0M<0.1%+1,463,117+44.7%AddedHolders
Q1 20253,272,194$71.6M<0.1%+685,455+26.5%AddedHolders
Q4 20242,586,739$82.5M<0.1%+2,272,055+722.0%AddedHolders
Q3 2024314,684$9.08M<0.1%+42,287+15.5%AddedHolders
Q2 2024272,397$10.4M<0.1%+161,105+144.8%AddedHolders
Q1 2024111,292$6.54M<0.1%+16,258+17.1%AddedHolders
Q4 202395,034$5.69M<0.1%+91,168+2,358.2%AddedHolders
Q3 20233,866$147.1K<0.1%−92,589−96.0%ReducedHolders
Q2 202396,455$8.79M<0.1%−7,909−7.6%ReducedHolders
Q1 2023104,364$6.88M<0.1%−27,533−20.9%ReducedHolders
Q4 2022131,897$6.82M<0.1%+117,258+801.0%AddedHolders
Q3 202214,639$1.00M<0.1%−57,484−79.7%ReducedHolders
Q2 202272,123$3.26M<0.1%−42,526−37.1%ReducedHolders
Q1 2022114,649$5.83M<0.1%+5,262+4.8%AddedHolders
Q4 2021109,387$5.17M<0.1%−87,495−44.4%ReducedHolders
Q3 2021196,882$6.49M<0.1%+140,763+250.8%AddedHolders
Q2 202156,119$3.55M<0.1%+44,425+379.9%AddedHolders
Q1 202111,694$502.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.